ABSTRACT
BACKGROUND Intravenous iron therapy represents a promising potential treatment option for patients with heart failure (HF) and iron deficiency (ID), as it has been shown to improve clinical symptoms and enhance quality of life. To investigate the benefits of intravenous iron therapy on hard cardiovascular endpoints in HF and ID patients, we conducted a systematic review and meta-analysis of randomized controlled trials (RCTs).
METHODS We implemented a systematical search of the PubMed, Embase and Cochrane Library databases for relevant RCTs of intravenous iron therapy in patients with HF and ID published from inception through January 20, 2024. Our primary endpoints of interest were HF hospitalizations, all-cause mortality, HF hospitalizations and cardiovascular death, cardiovascular hospitalizations and cardiovascular death. Sensitivity analyses and subgroup analyses were further performed to investigate additional clinical benefits in specific populations.
RESULTS Eleven trials encompassing a collective cohort of 6511 participants met our predefined eligibility criteria and were included in our meta-analysis. The predominant form of intravenous iron utilized in the trials included in our analysis was ferric carboxymaltose. Intravenous iron therapy yielded a 40% relative reduction in HF hospitalization (OR 0.60, 95% CI 0.51-0.70; P= 0.00001), a 46% relative reduction in HF hospitalizations and cardiovascular death (OR 0.54, 95% CI 0.46-0.63; P<0.00001) and a 53% relative reduction in cardiovascular hospitalizations and cardiovascular death (OR 0.47, 95% CI 0.37-0.59; P<0.00001). Our analysis revealed no statistically significant differences in terms of all-cause mortality (OR 0.85, 95% CI 0.72-1.01; P=0.06) while this result was fragile (reverse fragility index of 2 and reverse fragility quotient of 0.0004). Subgroup analyses revealed more favorable effects of intravenous iron therapy in trials that had a follow-up duration of ≥ 24 weeks and a sample size of over 200 cases. Intravenous iron therapy had negligible effects on infection (OR 0.86, 95% CI 0.66-1.11; P=0.25), general disorders and administration site conditions (OR 1.35, 95% CI 0.93-1.94; P=0.11), injury, poisoning and procedural complications (OR 0.96, 95% CI 0.66-1.40; P=0.85).
CONCLUSION Intravenous iron therapy in patients with HF and ID shows a significant reduction of rehospitalization for HF and cardiovascular death. The ferric carboxymaltose holds significant promise as a potential therapeutic agent for HF patients with ID.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Key Research and Development Program of China (grant numbers 2021YFC2701700 and 2021YFC2701703). None of the authors at any time received payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Chinese PLA General Hospital & Chinese PLA Medical School
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
We extracted data from publicly available randomized controlled studies. All types of data in this manuscript are publicly available
